This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Wed, 09/20/2023 - 09:56 September 20, 2023 — RefleXion Medical , Inc., Using its technology platform, 3BP has discovered and characterized a large portfolio of FAP-targeting molecules as potential diagnostic and therapeutic radiopharmaceuticals. For more information: [link] Wednesday, September 20, 2023 - 09:56
milla1cf Tue, 07/25/2023 - 20:22 July 25, 2023 — Ratio Therapeutics Inc. By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers.
In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7% from 1,401 estimated PET scans per system in 2022 to 1,495 in 2023. Davin Korstjens. physicians reading PET scans per site.
milla1cf Thu, 07/20/2023 - 20:11 July 20, 2023 — The members of the American Society for Radiation Oncology ( ASTRO ) recently elected three new officers to ASTRO’s Board of Directors, including Sameer Keole , MD, FASTRO , as President-elect; Wendy Woodward , MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S.
milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc. By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers.
milla1cf Tue, 05/23/2023 - 11:36 May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages , according to a new national survey from the American Society for Radiation Oncology ( ASTRO ). Radiation oncologists from across the country are in Washington, D.C.
SCINTIX therapy, delivered by the RefleXion X1, uses emissions from cancer cells created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that continuously and autonomously targets the cancer itself. The company will also hold multi-target SCINTIX technology interactive demonstrations in booth #501. “As
Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Underwood led the nuclear medicine and radiopharmaceutical therapy team within radiation safety at Mayo Clinic and directly supports the program in Rochester.
milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 for use in radiopharmaceutical therapy (RPT). actinium-225 (Ac-225). As a company at the forefront of U.S.
Other technologies use anatomical images to guide radiotherapy delivery; however, SCINTIX therapy is the only radiotherapy to use emissions from cancer cells, created by injecting the patient with a radiopharmaceutical, to deliver a radiation dose that continuously and autonomously targets the cancer itself.
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1
milla1cf Wed, 08/30/2023 - 14:45 August 30, 2023 — A published study by researchers at the University of Cincinnati Cancer Center and Cincinnati Children’s Hospital Medical Center shows that multiple beams and intervals in delivery during FLASH proton therapy treatment reduced skin-saving effects in preclinical models.
Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.
Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.
Once securely attached to a targeting molecule, the chelated Cu-67 delivers therapeutic doses of radiation to destroy cancer cells with limited damage to healthy tissue. It supports a sustainable future for radiopharmaceuticals unencumbered by manufacturing, logistical and environmental issues inherent to many radiopharmaceuticals.
milla1cf Wed, 08/23/2023 - 19:19 August 23, 2023 — RefleXion Medical , a therapeutic oncology company, today announced that the first patient has completed treatment with SCINTIX biology-guided radiotherapy on the RefleXion X1 machine at the Stanford Medicine Cancer Center.
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 Gauden , D.Phil.,
from October 1 to 4, 2023. from October 1 to 4, 2023. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga., Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga., Gauden , D.Phil.,
milla1cf Sun, 11/26/2023 - 09:00 November 26, 2023 — TeleDaaS, PLLC , a leading dosimetry-as-a-service provider, made its official debut today at the Radiological Society of North America’s annual meeting, # RSNA2023. This is already showing promise with several ongoing trials of approved and developmental radiopharmaceuticals.
Horowitz, et al, Medical Hypotheses , October 13, 2023. Plesner, et al, Radiology , September 26, 2023. Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers. Kochanova, et al, Scientific Reports , September 19, 2023. Huang, et al, JAMA Network Open , October 5, 2023.
He's also won the award five times under the Best Educational Mobile App category (2023, 2020, 2019, 2017, and 2016), once for Most Influential Radiology Researcher (2004), and once under the category of Best Radiology Image (2017). Elliot Fishman, MD.
Food and Drug Administration (FDA) on May 25, 2023. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023. POSLUMA use contributes to a patient’s overall long-term cumulative radiation exposure. POSLUMA was approved by the U.S. manufacturer and distributor.
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. manufacturer and distributor, PETNET Solutions Inc, A Siemens Healthineers Company.
Specifically, the purpose of dosimetry in radiotherapy is to estimate the amount of dose that will be absorbed by normal tissues and tumors to anticipate the biologic effects of radiation. Dosimetry in Radiopharmaceutical Therapy. 2023 May 22;68(11). J Nucl Med. 2022 Oct;63(10):1467-1474. doi: 10.2967/jnumed.121.262305.
Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., The acquisition closed on May 4, 2023.
Pete has over 20 years in the nuclear pharmacy industry and over 15 years in nuclear pharmacy management including expertise in logistics, complex supply chain management and radiopharmaceutical drug chemistry and formulation. Pete assumed the role of Vice President of Pharmacy Operations in 2023.
We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.”
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Standardized guidelines can help radiologists navigate the legal landscape of imaging pregnant women with ionizing radiation, according to a July 15 editorial published in the Journal of the American College of Radiology ( ACR ). The ACR and SPR in 2023 updated their practice parameter for this area of imaging.
About Targeted Alpha Therapy Targeted Alpha Therapy is an emerging class of cancer therapeutics, which seeks to deliver alpha radiation directly to the tumor while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g.,
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content